Literature DB >> 29559343

Neutrophil Adhesion Is a Prerequisite for Antibody-Mediated Proteolytic Tissue Damage in Experimental Models of Epidermolysis Bullosa Acquisita.

Xinhua Yu1, Reza Akbarzadeh2, Mario Pieper3, Thomas Scholzen4, Stefanie Gehrig5, Carsten Schultz5, Detlef Zillikens6, Peter König3, Frank Petersen7.   

Abstract

Although uncontrolled proteolytic activity mediated by activated neutrophils is a major reason for tissue damage, therapeutic approaches using protease inhibitors are inefficient. Here, we investigated the role of the immune complex-induced neutrophil adhesion and protease release in tissue damage. We show both in vitro and in vivo that immune complex-mediated neutrophil adhesion to the target tissue depends on β2 integrins. Without affecting elastase or reactive oxygen species release, blocking of adhesion drastically inhibited tissue damage in an experimental model of autoantibody-mediated skin blistering disease. By using a cell-bound fluorescent resonance energy transfer-based elastase sensor, we detected elastase enzyme activity on the surface of adherent cells resistant to protease inhibitors. Inhibitor resistance was lost by CD18 blockade or deficiency in vitro and in vivo. Immune complex-induced neutrophil adhesion created an enclosed protected space between the cell and its target structure where proteinases and reactive oxygen species can execute their tissue-damaging effect. Because immune complex-induced neutrophil adhesion represents an indispensable step for tissue damage of many diseases, our findings may facilitate the development of strategies for the treatment of such disorders.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29559343     DOI: 10.1016/j.jid.2018.03.1499

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Neutrophil elastase contributes to the pathological vascular permeability characteristic of diabetic retinopathy.

Authors:  Haitao Liu; Emma M Lessieur; Aicha Saadane; Sarah I Lindstrom; Patricia R Taylor; Timothy S Kern
Journal:  Diabetologia       Date:  2019-10-14       Impact factor: 10.122

Review 2.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

3.  Granzyme B inhibition reduces disease severity in autoimmune blistering diseases.

Authors:  Sho Hiroyasu; Matthew R Zeglinski; Hongyan Zhao; Megan A Pawluk; Christopher T Turner; Anika Kasprick; Chiharu Tateishi; Wataru Nishie; Angela Burleigh; Peter A Lennox; Nancy Van Laeken; Nick J Carr; Frank Petersen; Richard I Crawford; Hiroshi Shimizu; Daisuke Tsuruta; Ralf J Ludwig; David J Granville
Journal:  Nat Commun       Date:  2021-01-12       Impact factor: 14.919

4.  Preventive but Not Therapeutic Topical Application of Local Anesthetics Can Inhibit Experimental Epidermolysis Bullosa Acquisita in Mice.

Authors:  Lifang Wen; Xiaoru Dong; Qing Li; Gabriele Schramm; Bing Zhang; Detlef Zillikens; Ralf J Ludwig; Frank Petersen; Xinhua Yu
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

5.  Neutrophil-Derived Proteases Contribute to the Pathogenesis of Early Diabetic Retinopathy.

Authors:  Emma M Lessieur; Haitao Liu; Aicha Saadane; Yunpeng Du; Jie Tang; Jianying Kiser; Timothy S Kern
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-10-04       Impact factor: 4.925

6.  Subcutaneous injection of an immunologically tolerated protein up to 5 days before skin injuries improves wound healing.

Authors:  K Franco-Valencia; I B C Nóbrega; T Cantaruti; A Barra; A Klein; G M Azevedo-Jr; R A Costa; C R Carvalho
Journal:  Braz J Med Biol Res       Date:  2022-02-09       Impact factor: 2.590

Review 7.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.